4/A: Sana Biotechnology Director Michelle Seitz Corrects Stock Option Acquisition in Amended SEC Filing

Michelle Seitz, a director at Sana Biotechnology, files an amended Form 4 to correct the number of stock options acquired on June 6, 2024.

Summary

• Michelle Seitz, a director of Sana Biotechnology, Inc., filed an amended Form 4 with the SEC.
• The amendment corrects a clerical error regarding the number of stock options acquired on June 6, 2024.
• The corrected filing shows the acquisition of 65,000 stock options with an exercise price of $7.36.
• These options vest and become exercisable on the earlier of June 6, 2025, or immediately prior to the 2025 annual meeting of stockholders, contingent upon continuous service to Sana.
• Following the reported transaction, Seitz directly owns 65,000 derivative securities.

Sentiment

Score: 7

Explanation: The document is a routine regulatory filing correcting a clerical error, indicating standard corporate governance practices. There is no indication of positive or negative sentiment.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in the biotechnology industry.

Stakeholder Impact

• The correction of the stock option grant ensures accurate reporting to shareholders.

Key Dates